MaxCyte Presents Updates on First-in-class CARMA™ Platform at Upcoming Meetings
Clinical-stage CARMA platform delivers non-viral mRNA-based cell therapies Faster manufacturing speeds, broader therapeutic applications, combination opportunities and repeat dosing potential
Gaithersburg, Maryland – 30 September 2019 – MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company, announces its planned participation at five upcoming meetings. These conferences and events will demonstrate how MaxCyte is driving the development of the next generation of cell-based medicines with its proprietary CARMA™ platform.
CARMA is MaxCyte’s clinical-stage, non-viral, mRNA-based cell therapy platform that allows for the transfection of mRNA into cells and provides a simple, rapid-to-manufacture, dose-controllable product. CARMA requires less than one day to manufacture therapies for patients, where existing CAR-T therapies require one to two weeks or more to manufacture. MaxCyte’s wholly-owned lead CARMA candidate, MCY-M11, is currently being evaluated in a Phase I clinical trial in patients with advanced ovarian cancer and peritoneal mesothelioma.
Details of the conferences are as follows:
ESMO Congress 2019 27 September – 1 October 2019, Barcelona, Spain Christina M. Annunziata, MD, PhD, Head, Translational Genomics Section, Investigator, Women’s Malignancies Branch, National Cancer Institute, National Institutes of Health, will present a trials-inprogress poster titled: “A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy.”
The poster session will take place at 12:20 p.m. CET on 30 September. The poster will be available after the conference on the Events section of the MaxCyte website.
For more information, please visit: https://www.esmo.org/Conferences/ESMO-Congress-2019
Cell & Gene Meeting on the Mesa
2 – 4 October 2019, Carslbad, California MaxCyte’s CEO Doug Doerfler will present the CARMA pipeline on Wednesday, 2 October at 2:15 p.m. PT. For more information, please visit: https://www.meetingonthemesa.com/
BIO Investor Forum 22 – 23 October 2019, San Francisco, California MaxCyte’s CEO Doug Doerfler will present to attendees on the CARMA pipeline.
The timing of the presentation will be made available closer to the start of the conference. For more information, please visit: https://www.bio.org/events/bio-investor-forum
Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting/SITC 2019
6 – 10 November 2019, National Harbor, MD MaxCyte Director Technical Operations Robert Keefe, PhD, will present a poster titled: “Single-day CAR manufacturing platform using mRNA and Flow Electroporation Technology” on Saturday, 9 November from 7 a.m. to 8:30 p.m. ET. For more information, please visit: https://www.sitcancer.org/2019/home
11 – 13 November 2019, Hamburg Germany MaxCyte CEO Doug Doerfler will present to attendees on the CARMA pipeline. The timing of the presentation will be made available closer to the start of the conference. For more information, please visit: https://ebdgroup.knect365.com/bioeurope/
MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte’s mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including five commercial licenses. Aggregate potential pre-commercial milestones from all license deals total more than $450m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.